サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1390756

抗体薬物複合体市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Antibody Drug Conjugates Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 140 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗体薬物複合体市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

抗体薬物複合体の世界市場規模は2022年に63億米ドルに達しました。今後、IMARC Groupは、市場は2028年までに224億米ドルに達し、2022～2028年の成長率（CAGR）は23.54%になると予測しています。

抗体薬物複合体（ADC）は、細胞毒性を持つエフェクター分子に化学的に結合した腫瘍標的抗体からなる非常に強力な生物学的薬剤です。ADCは、生分解性リンカーを介してモノクローナル抗体（mAb）に結合させ、健常組織と病変組織との間の高感度な分岐を可能にすることで、罹患細胞に細胞毒性抗がん剤を送達します。このリンカーは、標準的な化学療法の生物活性化合物と比較して、mAbの殺細胞能力を高め、薬物の忍容性を向上させ、系統的な曝露を制限するのに役立ちます。現時点では、胃酸やタンパク質分解酵素によるmAbの分解を避けるため、血流にのせて静脈内投与されます。

抗体薬物複合体の市場動向：

座りがちなライフスタイルや、喫煙や飲酒を常習とする人の増加により、世界中でがんの有病率が増加しています。これは、費用対効果が高く成功率の高いがん治療に対する需要の高まりと相まって、市場の成長を後押しする重要な要因の一つとなっています。これとは別に、既存のリンカーはしばしばペイロードを非特異的に放出し、標的外毒性につながるため、ADCの開発に深刻な影響を与えています。その結果、大手企業は研究開発（R&D）プロジェクトに継続的に資金を投入し、既存の化学的トリガーを最適化したり、新規の化学的トリガーを開発したりして、選択性の高いリンカーを生み出しています。また、安定で均質なADCを製造するための新規リンカー-抗体結合体や、ペイロードの拡張を可能にする追加リンカー-ペイロード結合体も開発されています。さらに、吸収、分布、代謝、排泄の改善にも注力しており、市場の見通しは良好です。その他の主な要因としては、ヘルスケアインフラの大幅な改善、がん治療に利用可能な治療法に関する意識の高まり、開裂可能なリンカー技術のイントロダクションなどが挙げられ、市場の成長を促進すると予想されています。

本レポートで扱う主な質問

  • 抗体薬物複合体の世界市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の抗体薬物複合体市場に与えた影響は？
  • 主要な地域市場は？
  • コンポーネント別の市場内訳は？
  • ターゲット別の市場内訳は？
  • 用途別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の抗体薬物複合体市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 抗体薬物複合体の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：コンポーネント別

  • モノクローナル抗体
    • 市場動向
    • 市場予測
  • リンカー
    • 市場動向
    • 市場予測
  • 細胞毒性剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：ターゲット別

  • 抗体-タンパク質毒素コンジュゲート
    • 市場動向
    • 市場予測
  • 抗体-放射性核種コンジュゲート
    • 市場動向
    • 市場予測
  • 抗体-低分子薬物コンジュゲート
    • 市場動向
    • 市場予測
  • 抗体-酵素コンジュゲート
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • リンパ腫
    • 市場動向
    • 市場予測
  • 卵巣がん
    • 市場動向
    • 市場予測
  • 肺がん
    • 市場動向
    • 市場予測
  • 乳がん
    • 市場動向
    • 市場予測
  • 脳腫瘍
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • がん専門医療機関
    • 市場動向
    • 市場予測
  • 学術研究機関
    • 市場動向
    • 市場予測
  • バイオテクノロジー企業
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • ADC Therapeutics SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Celldex Therapeutics Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • ImmunoGen Inc
    • Pfizer Inc.
    • Sanofi S.A.
    • Seagen Inc.
    • Sorrento Therapeutics Inc.
    • Takeda Pharmaceutical Company Ltd.
図表

List of Figures

  • Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
  • Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2022
  • Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2022
  • Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2022
  • Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2022
  • Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2022
  • Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
  • Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
  • Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million US$), 2023-2028
  • Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million US$), 2023-2028
  • Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
  • Table 8: Global: Antibody Drug Conjugates Market: Key Players
目次
Product Code: SR112023A4604

Abstract

The global antibody drug conjugates market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.4 Billion by 2028, exhibiting a growth rate (CAGR) of 23.54% during 2022-2028.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, target, application and end user.

Breakup by Component:

Monoclonal Antibodies

Linker

Cytotoxic Agent

Others

Breakup by Target:

Antibody-Protein Toxin Conjugates

Antibody-Chelated Radionuclide Conjugates

Antibody-Small-Molecule Drug Conjugates

Antibody-Enzyme Conjugates

Breakup by Application:

Lymphoma

Ovarian Cancer

Lung Cancer

Breast Cancer

Brain Tumor

Others

Breakup by End User:

Hospitals

Specialized Cancer Centers

Academic Research Institutes

Biotechnology Companies

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

  • How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antibody drug conjugates market?
  • What are the key regional markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the target?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global antibody drug conjugates market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Linker
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic Agent
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Target

  • 7.1 Antibody-Protein Toxin Conjugates
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antibody-Chelated Radionuclide Conjugates
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antibody-Small-Molecule Drug Conjugates
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibody-Enzyme Conjugates
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ovarian Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lung Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Breast Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Brain Tumor
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialized Cancer Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Research Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Biotechnology Companies
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 ADC Therapeutics SA
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Astellas Pharma Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Celldex Therapeutics Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gilead Sciences Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 ImmunoGen Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Seagen Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sorrento Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
    • 15.3.13 Takeda Pharmaceutical Company Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis